home All News open_in_new Full Article

AAVantgarde presents updated positive clinical data from its AAVB

MILAN, Sept. 05, 2025 (GLOBE NEWSWIRE) — AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced the presentation of updated clinical data from the LUCE-1 study at the 25th European Society of Retina Specialists (EURETINA) Annual Congress (EURetina 2025), taking place in Paris 4-7 September 2025. Data […]


today 9 d. ago attach_file Other

attach_file Culture
attach_file Events
attach_file Economics
attach_file Economics
attach_file Politics
attach_file Science
attach_file Other
attach_file Economics
attach_file Other
attach_file Society
attach_file Other
attach_file Other
attach_file Technology
attach_file Sport
attach_file Economics
attach_file Economics
attach_file Culture
attach_file Culture
attach_file Sport
attach_file Politics


ID: 1622749287
Add Watch Country

arrow_drop_down